Publication | Open Access

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

HepatologyMedicineSorafenib TreatmentClinical TrialsPharmacotherapyLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaHealth Sciences